{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:10:11Z","timestamp":1761898211965,"version":"build-2065373602"},"reference-count":23,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T00:00:00Z","timestamp":1385856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T00:00:00Z","timestamp":1385856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics and Research in Hepatology and Gastroenterology"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1016\/j.clinre.2013.03.003","type":"journal-article","created":{"date-parts":[[2013,5,25]],"date-time":"2013-05-25T00:27:16Z","timestamp":1369441636000},"page":"614-618","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Retrospective analysis of survival benefits of chemotherapy for metastatic or non-resectable intrahepatic cholangiocarcinoma"],"prefix":"10.1016","volume":"37","author":[{"given":"Nadia","family":"Wiazzane","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Chauffert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois","family":"Ghiringhelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinre.2013.03.003_bib0005","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1097\/MOG.0b013e3280495451","article-title":"Cholangiocarcinoma: emerging approaches to a challenging cancer","volume":"23","author":"Patel","year":"2007","journal-title":"Curr Opin Gastroenterol"},{"key":"10.1016\/j.clinre.2013.03.003_bib0010","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1097\/00000658-200110000-00010","article-title":"Staging, resectability, and outcome in 225 patients with hilarcholangiocarcinoma","volume":"234","author":"Jarnagin","year":"2001","journal-title":"Ann Surg"},{"key":"10.1016\/j.clinre.2013.03.003_bib0015","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1111\/j.1365-2036.2006.02900.x","article-title":"Review article: the modern diagnosis and therapy of cholangiocarcinoma","volume":"23","author":"Malhi","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.clinre.2013.03.003_bib0020","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1097\/COC.0b013e318162f57d","article-title":"Phase II study of oxaliplatin in patients with unresectable, metastatic, or recurrent hepatocellular cancer: a California Cancer Consortium Trial","volume":"31","author":"Yen","year":"2008","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.clinre.2013.03.003_bib0025","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/01.coc.0000258124.72884.7a","article-title":"Irinotecan with 5-FU\/FA in advanced biliary tract adenocarcinomas: a multicentre phase II trial","volume":"30","author":"Feisthammel","year":"2007","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.clinre.2013.03.003_bib0030","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1093\/annonc\/mdh351","article-title":"Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study","volume":"15","author":"Andr\u00e9","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clinre.2013.03.003_bib0035","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1093\/oxfordjournals.annonc.a010676","article-title":"Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer","volume":"7","author":"Glimelius","year":"1996","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clinre.2013.03.003_bib0040","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1093\/jjco\/hym116","article-title":"A multi-centre retrospective analysis of survival benefits of chemotherapy for unresectable biliary tract cancer","volume":"37","author":"Yonemoto","year":"2007","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.clinre.2013.03.003_bib0045","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinre.2013.03.003_bib0050","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.gcb.2009.05.012","article-title":"[Current management and prognosis of intrahepatic cholangiocarcinoma in France]","volume":"33","author":"Borie","year":"2009","journal-title":"Gastroenterol Clin Biol"},{"key":"10.1016\/j.clinre.2013.03.003_bib0055","doi-asserted-by":"crossref","DOI":"10.1038\/sj.bjc.6604628","article-title":"Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II study","author":"Andr\u00e9","year":"2008","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clinre.2013.03.003_bib0060","doi-asserted-by":"crossref","first-page":"7753","DOI":"10.1200\/JCO.2005.02.7524","article-title":"Gallbladder cancer, a different disease that needs individual trials","volume":"23","author":"Gallardo","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinre.2013.03.003_bib0065","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1097\/01.cco.0000129679.49651.50","article-title":"Biliary tract neoplasms: update 2003","volume":"16","author":"Malka","year":"2004","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.clinre.2013.03.003_bib0070","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1053\/sonc.2002.37380","article-title":"Review of gemcitabine in biliary tract carcinoma","volume":"29","author":"Scheithauer","year":"2002","journal-title":"Semin Oncol"},{"key":"10.1016\/j.clinre.2013.03.003_bib0075","doi-asserted-by":"crossref","first-page":"4089","DOI":"10.1200\/JCO.2001.19.20.4089","article-title":"Treatment of inoperable and\/or metastatic biliary tree carcinomas with single agent gemcitabine or in combination with levofolinic acid and infusional fluorouracil: results of a multicentre phase II study","volume":"19","author":"Gebbia","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinre.2013.03.003_bib0080","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.ejca.2004.10.026","article-title":"A randomised phase II trial of weekly high-dose 5-fluorouracil with and without folinic acid and cisplatin in patients with advanced biliary tract carcinoma: results of the 40955 EORTC trial","volume":"41","author":"Ducreux","year":"2005","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clinre.2013.03.003_bib0085","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1200\/JCO.1996.14.8.2306","article-title":"Phase II study of paclitaxel therapy for unresectable biliary tree carcinomas","volume":"14","author":"Jones","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinre.2013.03.003_bib0090","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1093\/oxfordjournals.annonc.a058597","article-title":"Phase II trial of mitomycin C (MMC) in advanced gallbladder and biliary tree carcinoma. An EORTC Gastrointestinal Tract Cancer Cooperative Group study","volume":"4","author":"Taal","year":"1993","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clinre.2013.03.003_bib0095","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1385\/IJGC:32:2-3:107","article-title":"CPT-11 for bile duct and gallbladder carcinoma: a phase II North Central Cancer Treatment Group study (NCCTG)","volume":"32","author":"Alberts","year":"2002","journal-title":"Int J Gastrointest Cancer"},{"key":"10.1016\/j.clinre.2013.03.003_bib0100","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1016\/S0959-8049(01)00214-3","article-title":"First-line chemotherapy with docetaxel for unresectable or metastatic carcinoma of the biliary tract. A multicentre phase II study","volume":"37","author":"Papakostas","year":"2001","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clinre.2013.03.003_bib0105","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/sj.bjc.6604178","article-title":"Capecitabine plus oxaliplatin as first-line treatment in patients with advanced biliary system adenocarcinoma: a prospective multicentre phase II trial","volume":"98","author":"Nehls","year":"2008","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clinre.2013.03.003_bib0110","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1038\/sj.bjc.6603648","article-title":"Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials","volume":"96","author":"Eckel","year":"2007","journal-title":"Br J Cancer"},{"issue":"15s","key":"10.1016\/j.clinre.2013.03.003_bib0115","doi-asserted-by":"crossref","first-page":"4503","DOI":"10.1200\/jco.2009.27.15_suppl.4503","article-title":"Gemcitabine with or without cisplatin in patients (pts) with advanced or metastatic biliary tract cancer (ABC): Results of a multicentre, randomized phase III trial (the UK ABC-02 trial)","volume":"27","author":"Valle","year":"2009","journal-title":"J Clin Oncol"}],"container-title":["Clinics and Research in Hepatology and Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740113000545?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740113000545?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:18:22Z","timestamp":1761895102000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2210740113000545"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["S2210740113000545"],"URL":"https:\/\/doi.org\/10.1016\/j.clinre.2013.03.003","relation":{},"ISSN":["2210-7401"],"issn-type":[{"type":"print","value":"2210-7401"}],"subject":[],"published":{"date-parts":[[2013,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Retrospective analysis of survival benefits of chemotherapy for metastatic or non-resectable intrahepatic cholangiocarcinoma","name":"articletitle","label":"Article Title"},{"value":"Clinics and Research in Hepatology and Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinre.2013.03.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Published by Elsevier Masson SAS","name":"copyright","label":"Copyright"}]}}